Lyell Immunopharma (LYEL) Other Non Operating Income (2020 - 2026)
Lyell Immunopharma recorded quarterly Other Non Operating Income of $17.9 million in Q1 2026, up 213.7% quarter-over-quarter from -$15.8 million in Q4 2025, and up 1267.48% year-over-year from $1.3 million in Q1 2025.
Lyell Immunopharma's Other Non Operating Income history runs 7 years deep, the most recent figure standing at $17.9 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 1267.48% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at -$1.5 million (down 130.93% YoY), while the FY2025 annual figure was -$18.1 million, down 486.11% from the prior year.
- Other Non Operating Income came in at $17.9 million for Q1 2026 at Lyell Immunopharma, up from -$15.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $17.9 million in Q1 2026 to a low of -$15.8 million in Q4 2025.
- A 5-year average of $483352.9 and a median of $35000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income soared 6768.18% in 2022 and tumbled 11200.0% in 2025, its largest moves.
- Lyell Immunopharma's Other Non Operating Income stood at $2.9 million in 2022, then plunged by 117.25% to -$506000.0 in 2023, then jumped by 948.22% to $4.3 million in 2024, then tumbled by 467.08% to -$15.8 million in 2025, then surged by 213.7% to $17.9 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $17.9 million, -$15.8 million, and -$4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.91 Mn |
| Dec 31, 2025 | -15.76 Mn |
| Sep 30, 2025 | -4.86 Mn |
| Jun 30, 2025 | 1.18 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 4.29 Mn |
| Sep 30, 2024 | -43,000.00 |
| Jun 30, 2024 | -645,000.00 |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | -506,000.00 |
| Sep 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | -326,000.00 |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 2.93 Mn |
| Sep 30, 2022 | -1.07 Mn |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | 35,000.00 |
| Dec 31, 2021 | -44,000.00 |
| Sep 30, 2021 | 16,000.00 |
| Jun 30, 2021 | -106,000.00 |
| Mar 31, 2021 | -27,000.00 |
| Dec 31, 2020 | 46,000.00 |
| Sep 30, 2020 | 28,000.00 |
| Jun 30, 2020 | 29,000.00 |